{"disease":{"id":"plague","name":"Plague","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"doxycycline","indication_name":"Plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"moxifloxacin","indication_name":"Pneumonic plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Septicemic plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"avelox","indication_name":"Pneumonic plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Septicemic plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"minocycline","indication_name":"Plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"minocyclin","indication_name":"Plague","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05330624","title":"Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":720,"lead_sponsor_name":"Jiangsu Province Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT07174648","title":"Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT04110340","title":"Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05506969","title":"Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Dynavax Technologies Corporation","has_results":true},{"nct_id":"NCT07207408","title":"Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"Dynavax Technologies Corporation","has_results":false}],"total":5},"guidelines":[{"drug_id":"levofloxacin","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for plague, including pneumonic and septicemic plague, due to Yersinia pestis.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"levofloxacin-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Levofloxacin is indicated for the treatment of plague in adult and pediatric patients.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}